Arrow-right Camera
The Spokesman-Review Newspaper

The Spokesman-Review Newspaper The Spokesman-Review

Spokane, Washington  Est. May 19, 1883
Partly Cloudy Day 70° Partly Cloudy
News >  Business

Motley Fool: A pharmaceutical bargain

Pfizer has laid out a strong case explaining why its five core growth products should deliver top-line growth of at least 6% per year for the next five years. (Associated Press)
Pfizer has laid out a strong case explaining why its five core growth products should deliver top-line growth of at least 6% per year for the next five years. (Associated Press)

Big pharma titan Pfizer (NYSE: PFE) has had a dismal year. The company’s shares were recently down more than 35% from their 52-week high, reaching a five-year low. Apart from the coronavirus-induced sell-off, Pfizer’s shares have also suffered from a lack of confidence among investors.

Possible government price controls are one worry, but there’s also Pfizer’s plan to spin off its generic drug business Upjohn, pairing it with Mylan and forming a new entity called Viatris. As this move will significantly shrink the company’s annual revenue, investors appear to be concerned about the sustainability of Pfizer’s top-notch dividend (recently yielding 4.1%), along with its prospects as a growth-oriented branded drug company.

These concerns are likely way overblown, though. First, current Pfizer shareholders will own a piece of Viatris. That’s important because the combined yield of Pfizer and Viatris should at least equal – and quite possibly exceed – the company’s current annualized payout.

Also, Pfizer has laid out a strong case explaining why its five core growth products – Vyndaqel, Ibrance, Xeljanz, Eliquis and Prevnar – should deliver top-line growth of at least 6% per year for the next five years. Once the global pandemic fades, Pfizer should come roaring back. (The Motley Fool has recommended Mylan.)

Ask the Fool

Q: What’s a company’s book value? – G.H., West Palm Beach, Florida

A: Book value is an accounting measure that investors sometimes look at to get an idea of a company’s intrinsic value. Boiled down, book value is simply the company’s total assets, less its total liabilities. It’s showing you what shareholders would own once debts and liabilities are covered.

Book value’s usefulness has shrunk somewhat as our economy has evolved. It worked well when most businesses were simpler and capital-intensive, with assets such as factories, equipment and land appearing on the balance sheet. It works less well today, though, as there are gobs of service-oriented companies and high-tech companies that are heavy on intangible assets, such as patents and goodwill (an accounting measure often tied to acquisitions).

Consider Facebook, with many assets that don’t register significantly on the balance sheet: intellectual property, employees, a strong brand and a massive worldwide network of customers. As of the end of 2019, its total assets were $133.4 billion and its total liabilities $32.3 billion, leaving a book value of $101.1 billion. That’s far less than its recent market value of roughly $540 billion.

Consider, too, a company that owns many buildings: Over the years, their value on the balance sheet is depreciated, eventually to zero. They’re not really worth zero, though, and they can even appreciate over time. Such a company can also be worth much more than its book value. With many companies, your best bet is to ignore book value.

Q: What’s an ETF? – R.M., Barre, Vermont

A: Exchange-traded funds, or ETFs, are bundles of securities, very much like mutual funds; the difference is that they trade like shares on a stock exchange.

My dumbest investment

My dumbest investment was not investing soon enough. I wanted to get into the market, but I was too nervous and constantly put it off. I wasted a few valuable years of gains. Now I spend time trying to get others comfortable with getting in! My lesson learned: Time is money. – K.D., online

The Fool responds: That’s a great lesson indeed.

Imagine that you start investing at age 40 and sock away $5,000 per year for 25 years, until you’re 65, and that you earn an average annual gain of 8%: You’d end up with nearly $400,000. But if you’d started five years earlier, at age 35, and saved and invested for a total of 30 years, you’d end up with more than $600,000 – a difference of more than $200,000!

No one should jump into the stock market until they’re comfortable with what they’re doing, so it’s smart to read up on the topic first – ideally, while you’re still young. You don’t even have to read and learn very much, if you just stick with low-fee, broad-market index mutual funds, such as ones that track the S&P 500.

Not everyone can sock away $5,000 annually, but invest however much you can, and remember that only money you won’t need for five (or even 10) years should be in stocks, as the market can be volatile.

The Spokesman-Review Newspaper

Local journalism is essential.

Give directly to The Spokesman-Review's Northwest Passages community forums series -- which helps to offset the costs of several reporter and editor positions at the newspaper -- by using the easy options below. Gifts processed in this system are not tax deductible, but are predominately used to help meet the local financial requirements needed to receive national matching-grant funds.

Active Person

Subscribe to the Coronavirus newsletter

Get the day’s latest Coronavirus news delivered to your inbox by subscribing to our newsletter.